OncLive TV

William M. Sikov, MD, discusses the benefit of CDK4/6 inhibitors in the treatment of hormone receptor–positive/HER2-negative breast cancers.

Pannaga G. Malalur, MBBS, discusses the implications of the findings for the use of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin in the frontline setting for patients with metastatic pancreatic ductal adenocarcinoma.

Gautam Borthakur, MD, discusses the ongoing phase 3 SELECT MDS-1 trial in patients with newly diagnosed myelodysplastic syndromes.

Dimitrios Nasioudis, MD, discusses how the use of next-generation sequencing can help identify the unique molecular profile of endometroid ovarian cancer.

Lindsey K. Buckingham, MD, discusses an investigation into the use of patient-reported outcomes from the cancer-specific Geriatric Assessment (GA) to predict frailty in women with ovarian cancer, as well as planning the next steps for this research in other gynecologic cancers.

Brian M. Slomovitz, MD, discusses the evaluation of letrozole and ribociclib from the phase 2 GOG 3026 trial in recurrent low-grade serous ovarian carcinoma.

Shannon N. Westin, MD, MPH, FACOG, discusses the outcomes of the phase 1b SOLAR trial, which examined olaparib with selumetinib in patients with RAS-mutant gynecologic malignancies and other solid tumors.

Pamela T. Soliman, MD, MPH, discusses the use of circulating tumor DNA a clinical trial end point in endometrial cancer.

Martin F. Dietrich, MD, PhD, discusses how mutational profiling can inform subsequent treatment selection for patients with non–small cell lung cancer.

Bruno B. Bockorny, MD, discusses findings from a phase 1a/b trial with the combination of botensilimab and balstilimab in patients with recurrent platinum-refractory or platinum-resistant ovarian cancer.

Mansoor Raza Mirza, MD, discusses findings from the phase 3 RUBY trial in patients with endometrial cancer.

Alaa Muslimani, MD, discusses the unmet needs for patients with HER2-positve metastatic colorectal cancer and highlights the implications of the phase 2 MOUNTAINEER trial in this patient population.

Alexandra Sokolova, MD,discusses the evaluation of rucaparib vs physician’s choice standard of care therapy in patients with BRCA-positive metastatic castration-resistant prostate cancer.

Andrew Kin, MD, discusses the withdrawal of the United States marketing authorization of belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Oliver Dorigo, MD, PhD, discusses the clinical efficacy of maveropepimut-S in patients with recurrent ovarian cancer.

Rosa M. Polan, MD, discusses key data from a comparison of perioperative outcomes with supracervical and total hysterectomy performed with concurrent colorectal resection in women.

Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.

Ursula A. Matulonis, MD, discusses final overall survival results from the phase 3 NOVA trial in patients with ovarian cancer.

Jorge E. Cortes, MD, discusses the importance of defining fitness in patients with hematologic malignancies prior to treatment selection.

R. Lor Randall, MD, FACS, discusses the potential symptoms and presentation of mesenchymal chondrosarcoma, as well as highlighted recent case studies that he consulted on for patients with mesenchymal chondrosarcoma.

Lisa A. Carey MD, ScM, FASCO, discusses the varying approaches to response-guided therapy in HER2-positive breast cancer.

Gregory Vidal, MD, PhD, explains why clinical trials need to be more representative of the whole breast cancer population, in order to account for differences in biology and social determinants.

Joshua Hill, MD, MS, discussed the early efficacy of dostarlimab in mismatch repair–deficient locally advanced rectal cancer.

Maya Khalil, MD, discusses key clinical trial updates on the use of nivolumab and ipilimumab with or without chemotherapy in non–small cell lung cancer.

Jeffery Zonder, MD, discusses the need for expanding the armamentarium of targeted therapies for patients with relapsed/refractory multiple myeloma.

Jeffery Zonder, MD, discusses the process of choosing between CAR T-cell therapy and bispecific antibody approaches for the treatment of patients with relapsed/refractory multiple myeloma.

Julie Renee Brahmer, MD, discusses the use of tremelimumab plus durvalumab and platinum-based chemotherapy for the first-line treatment of patients with non–small cell lung cancer, and how decisions can be made between this regimen and nivolumab plus ipilimumab and chemotherapy.

Brian Mitzman, MD, FACS, FCCP, discusses the emergence of immunotherapy as a treatment option for patients with early-stage non–small cell lung cancer.

Bradley W. Christensen, MD, discusses findings from the phase 3 VIALE-A trial in patients with acute myeloid leukemia.

Anne Chiang, MD, PhD, discusses recent advancements in the biological understanding and treatment of small cell lung cancer.